JP2012504941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504941A5 JP2012504941A5 JP2011530354A JP2011530354A JP2012504941A5 JP 2012504941 A5 JP2012504941 A5 JP 2012504941A5 JP 2011530354 A JP2011530354 A JP 2011530354A JP 2011530354 A JP2011530354 A JP 2011530354A JP 2012504941 A5 JP2012504941 A5 JP 2012504941A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- pharmaceutical composition
- administration
- human
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 241001465754 Metazoa Species 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 206010016654 Fibrosis Diseases 0.000 claims description 7
- 230000004761 fibrosis Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 229940080856 gleevec Drugs 0.000 claims description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101150018665 MAPK3 gene Proteins 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810200937.8 | 2008-10-09 | ||
| CN2008102009378A CN101392026B (zh) | 2008-10-09 | 2008-10-09 | 用于预防和治疗纤维化类疾病以及肝癌的多肽 |
| PCT/CN2009/074048 WO2010040305A1 (en) | 2008-10-09 | 2009-09-21 | Pharmaceutical being used for treating cancer and fibrosis disease and the composition and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012504941A JP2012504941A (ja) | 2012-03-01 |
| JP2012504941A5 true JP2012504941A5 (https=) | 2012-11-08 |
| JP5734856B2 JP5734856B2 (ja) | 2015-06-17 |
Family
ID=40492557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530354A Expired - Fee Related JP5734856B2 (ja) | 2008-10-09 | 2009-09-21 | 癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8637467B2 (https=) |
| EP (1) | EP2344528B1 (https=) |
| JP (1) | JP5734856B2 (https=) |
| CN (1) | CN101392026B (https=) |
| WO (1) | WO2010040305A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101392026B (zh) * | 2008-10-09 | 2011-11-09 | 黄岚 | 用于预防和治疗纤维化类疾病以及肝癌的多肽 |
| CN111701020A (zh) * | 2020-06-08 | 2020-09-25 | 南通大学 | 一种治疗pdgf诱导的肝纤维化的分子靶点 |
| CN120536440A (zh) * | 2025-05-23 | 2025-08-26 | 中山大学中山眼科中心 | 一种靶向pdgf-c抑制纤维化的核酸适配子及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| JP2002525086A (ja) * | 1998-09-30 | 2002-08-13 | ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ | 血小板由来増殖因子ｃ、それをコードするｄｎａ、及びその利用法 |
| US20030211994A1 (en) * | 1998-09-30 | 2003-11-13 | Ludwig Institute For Cancer Research | Composition and method for modulating vasculogenesis or angiogenesis |
| WO2000037641A2 (en) * | 1998-12-22 | 2000-06-29 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-x |
| CN1355209A (zh) * | 2000-11-24 | 2002-06-26 | 复旦大学 | 一种新的多肽——钙依赖性氯离子通道16.72和编码这种多肽的多核苷酸 |
| EP1513870A4 (en) * | 2002-05-31 | 2006-06-07 | Childrens Hosp Medical Center | CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES USEFUL FOR TREATING MUCOVISCIDOSE AND TECHNIQUES AND PRODUCTS FOR DETECTING AND / OR IDENTIFYING THESE |
| US20040248796A1 (en) | 2003-02-04 | 2004-12-09 | Kari Alitalo | VEGF-B and PDGF modulation of stem cells |
| EP1919944B1 (en) | 2005-08-15 | 2011-03-23 | Vegenics Pty Ltd | Modified vegf and pdgf with improved angiogenic properties |
| CN101392026B (zh) | 2008-10-09 | 2011-11-09 | 黄岚 | 用于预防和治疗纤维化类疾病以及肝癌的多肽 |
-
2008
- 2008-10-09 CN CN2008102009378A patent/CN101392026B/zh not_active Expired - Fee Related
-
2009
- 2009-09-21 EP EP09818769.3A patent/EP2344528B1/en not_active Not-in-force
- 2009-09-21 WO PCT/CN2009/074048 patent/WO2010040305A1/en not_active Ceased
- 2009-09-21 JP JP2011530354A patent/JP5734856B2/ja not_active Expired - Fee Related
- 2009-09-21 US US13/123,424 patent/US8637467B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011530599A5 (https=) | ||
| US20190309021A1 (en) | Composition Comprising a Peptide and an Inhibitor of Viral Neuraminidase | |
| JP2005527547A5 (https=) | ||
| JP5981141B2 (ja) | 多臓器不全症候群（ｍｏｄｓ）の予防および／または処置のためのインターロイキン−２２の使用 | |
| JP2012504941A5 (https=) | ||
| He et al. | C-fiber degeneration enhances alveolar macrophage-mediated IFN-α/β response to respiratory syncytial virus | |
| JP2013542196A5 (https=) | ||
| US11278542B2 (en) | Use of nicotinamide composition in preparation of drug for treating hand-foot skin reaction induced by sorafenib | |
| TWI496579B (zh) | 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途 | |
| JP2022524585A (ja) | 新規ペプチドおよびその用途 | |
| JP6484839B2 (ja) | 新規ペプチド及びその用途 | |
| JP2016516756A5 (https=) | ||
| RU2015146997A (ru) | Ингибиторы метастазирования | |
| JP2015524808A5 (https=) | ||
| CN118632704A (zh) | 寡肽与抗雄激素组合的药物用途 | |
| WO2006032525B1 (en) | Combinational therapy for treating cancer | |
| CN103371986B (zh) | 漆酚化合物在制备抑制肝脏组织纤维化的药物中的用途 | |
| Cirioni et al. | S-thanatin in vitro prevents colistin resistance and improves its efficacy in an animal model of Pseudomonas aeruginosa sepsis | |
| US11161881B2 (en) | Composition comprising a peptide and an inhibitor of viral neuraminidase | |
| EP3354268A1 (en) | Tumor prevention and treatment drug and applications thereof | |
| EP3113786B1 (en) | Attenuation of intrapulmonary inflammation | |
| CN103169970A (zh) | 一种治疗病毒性肺炎的药物组合物 | |
| CN118236470A (zh) | MOTS-c肽及其衍生物在制备支气管哮喘治疗药物中的应用 | |
| JP5500751B2 (ja) | 肝移植後の再感染防御剤 | |
| TW202207972A (zh) | Stat3之磷酸化抑制劑、自體免疫疾病及冠狀病毒傳染病之預防或治療劑 |